口服米非司酮配合局部注射无水乙醇治疗子宫内膜异位囊肿38例观察

目的：探讨米非司酮结合超声介入无水乙醇局部注射治疗子宫内膜异位囊肿的临床价值。方法：对58例盆腔子宫内膜异位囊肿行经阴道超声引导下囊肿穿刺、抽液并注射无水乙醇（硬化治疗）。治疗组38例于治疗当月起口服米非司酮（25mg,qd）3－6个月；对照组20例单行囊肿硬化治疗。随访2年，比较两组治疗后的复发率，观察米非司酮的辅助疗效及其副反应。结果：治疗组和对照组的复发率1年各为5．3％和30．0％，2年各为7．9％及35．0％，两组间比较有显著差异（P＜0．01）；治疗组1年及2年复发率比较无显著性差异（P＞0．05）。结论：加用米非司酮治疗3－6个月经周期可有效地降低子宫内膜异位囊肿穿刺硬化治疗的复发率，副反应轻。     

子宫动脉栓塞与子宫肌瘤剔除术治疗子宫肌瘤疗效对比分析

目的探讨子宫肌瘤子宫动脉栓塞治疗与子宫肌瘤剔除术治疗疗效.方法回顾分析40例(A组)经子宫动脉栓塞治疗、42例(B组)经腹腔镜子宫肌瘤剔除术、36例(C组)经阴式子宫肌瘤剔除术及30例(D组)经腹式子宫肌瘤剔除术治疗子宫肌瘤病例临床资料及随访情况,分析疗效.结果4组病例均保留子宫,临床症状均明显改善,且未出现明显并发症.术后随访3～24 个月(平均18个月),术后6个月,A组子宫及肌瘤体积缩小平均62%,6例肌瘤消失;B、C、D组子宫体积缩小平均84%.术后18个月,A组子宫及肌瘤体积缩小平均86%,子宫体积恢复正常大小23例,14例肌瘤消失,B、C、D组子宫体积恢复正常大小分别为30例、29例、23例,肌瘤复发分别为3例、2例、2例.结论子宫动脉栓塞治疗与子宫肌瘤剔除术治疗子宫肌瘤均有良好疗效,子宫肌瘤剔除术治疗子宫肌瘤后子宫体积恢复正常大小及肌瘤消失率较子宫动脉栓塞治疗法高,但近期复发率高于子宫动脉栓塞治疗法.     

绝经后妇女低剂量激素替代治疗的有效性与安全性的临床研究

目的：探讨绝经后妇女低剂量激素替代治疗的有效性与安全性。方法：４４例绝经后妇女随机分为两组,试验组２２例,隔日口服结合型雌激素（ＣＥ）０．６２５ｍｇ与安宫黄体酮（ＭＰＡ）２ｍｇ交替应用;对照组２２例,口服ＣＥ０．６２５ｍｇ／ｄ,每月连续服用２５天,后１０天加用ＭＰＡ４ｍｇ。两组均连续服用４周期。结果：实验组１例退出,对照组２例退出。两组比较治疗效果无差异（Ｐ＞０．０５）,治疗后绝经期症状均明显改善（Ｐ＜０．００１）;两组血清总胆固醇（ＴＣ）、甘油三酯（ＴＧ）、低密度脂蛋白（ＬＤＬ）均明显下降,两组ＨＤＬ无显著变化（Ｐ＞０．０５）;两组尿钙／肌酐（Ｃａ／Ｃｒ）值均明显下降;试验组副反应明显低于对照组;阴道出血试验组２例（９．１％）,对照组１４例（６３．６％,Ｐ＜０．００１）;乳房胀痛试验组１例（４．５％）,对照组７例（３１．８％,Ｐ＜０．００１）。两组用药后无血压升高、乳腺增生及子宫内膜增生。结论：绝经后妇女低剂量激素替代治疗具有用量小、副反应少、有效、安全、经济、依从性高等优点。     

促性腺激素释放激素激动剂延长用药间隔治疗子宫内膜异位症和子宫腺肌病的疗效观察

目的探讨促性腺激素释放激素激动剂(GnRHa)在治疗子宫内膜异位症(内异症)、子宫腺肌病和子宫肌瘤中的作用以及延长用药间隔对疗效的影响。方法内异症、子宫腺肌病和子宫肌瘤患者共70例,随机分为两组即延长用药间隔组(E组,30例)与常规用药组(C组,40例),分别用曲普瑞林3·75mg肌内注射4次(间隔6周)或6次(间隔4周),疗程均为24周,比较用药前后症状、子宫体积和病灶体积、血清生殖激素水平变化。结果E、C两组中内异症和子宫腺肌病患者的痛经缓解率均为100%;药物治疗结束时子宫体积平均缩小35%和37%,治疗前后比较,差异有统计学意义(P<0·05)。两组患者药物治疗前后血清卵泡刺激素(FSH)、黄体生成素(LH)、雌二醇水平,E组从用药前的(6·7±1·4)U/L、(4·713±1·048)U/L、(209±29)pmol/L,下降到第1次用药后6周的(2·1±0·5)U/L、(0·496±0·212)U/L、(95±18)pmol/L,分别与用药前比较,差异均有统计学意义(P<0·05);用药前及第1次用药后12、24、28周,E、C两组分别比较,差异均无统计学意义(P>0·05)。结论GnRHa通过降低血清FSH、LH和雌二醇水平而缓解痛经、缩小病灶;大多数患者用药间隔延长至6周对疗效无影响,并且可降低医疗费用,可在有血清生殖激素监测条件下推荐应用。     

未足月胎膜早破合并下生殖道感染对母婴结局的影响

目的探讨未足月胎膜早破（PPROM）合并下生殖道感染对母婴结局的影响。方法选取46例PPROM患者宫颈分泌物培养有菌生长者为研究组,62例培养无菌者为对照组,比较其母婴结局。结果研究组产后出血、产褥感染和绒毛膜羊膜炎发生率分别为23．91％（11／46）、15．22％（7／46）和6．52％（3／46）,对照组分别为14．52％（9／62）、16．13％（10／62）和17．74％（11／62）,两组比较,差异无统计学意义（P〉0．05）。研究组新生儿肺炎和死亡率分别为10．87％（5／46）和2．17％（1／46）,对照组分别为12．90％（8／62）和4．84％（3／62）,两组比较,差异无统计学意义（P〉0．05）。结论未足月胎膜早破合并下生殖道感染在积极抗感染及期待治疗下,未增加孕产妇和围生儿的发病率。     

米非司酮配伍与不配伍三苯氧胺治疗子宫肌瘤的临床观察

目的：探讨米非司酮酯伍或不配伍三苯氧胺治疗子宫肌瘤的临床效果。方法：将绝经前有症状的子宫肌瘤患者173例随机分成两组,A组：米非司酮组,88例,每天口服米非司酮25mg;B组,米非司酮配伍三苯氧胺组,85例,每天口服米非司酮25mg,同时口服三苯氧胺10mg,每日两次,从月经周期第一天开始,连服3个月。在治疗前后B超测量子宫体积、肌瘤体积;行子宫内膜病检观察子宫内膜变化;检测雌、孕激素水平,血红蛋白,肝肾功能,观察服药后的副反应。结果：两组患者治疗期间均闭经,子宫内膜及雌孕激素水平维持于增殖早期,血红蛋白上升。两组治疗后子宫体积、最大肌瘤的平均体积缩小。治疗后两组之间差异有显著性（P＜0.01),B组子宫和最大肌瘤的体积缩小较小。两组副反应类似且无需特殊处理。结论：米非司酮配伍或不配伍三苯氧胺治疗子宫肌瘤均有较好的临床效果,米非司酮配伍三苯氧胺是更合理的方法。     

两种不同剂量米非司酮治疗子宫肌瘤的疗效观察

目的：观察两种不同剂量米非司酮治疗子宫肌瘤的效果。方法：将４３例有症状的子宫肌瘤患者非随机分为两组进行前瞻性研究。甲组２８例，每天服用米非司酮１０ｍｇ；乙组１５例，每天服用米非司酮２０ｍｇ。从月经第１～３天开始服用，连续服用３个月。于治疗前以及治疗期间的每个月行Ｂ超测量子宫和子宫肌瘤的体积；检查血红蛋白及肝、肾功能。结果：两组患者在治疗期间均闭经，痛经和下腹坠、胀痛症状消失。所有患者的贫血均得以纠正，平均血红蛋白每月上升１４～１６ｇ／Ｌ。用药３个月后，两组子宫及子宫肌瘤体积均明显缩小，甲组肌瘤缩小了４１．４％（Ｐ＜０．０１），乙组肌瘤缩小了４３．０％（Ｐ＜０．０１）；两组之间差异无显著性。两组患者出现的副反应类似。结论：每日口服米非司酮１０ｍｇ是较为理想的治疗剂量，适合于肌瘤较大和（或）严重贫血患者术前准备及围绝经期有症状子宫肌瘤患者的保守治疗     

米非司酮与长效GnRH-a治疗子宫肌瘤的疗效观察

目的：探讨米非司酮与长效促性腺激素释放激素激动剂（长效GnRH-a） 治疗子宫肌瘤的临床效果及副作用。方法：将81例确诊为子宫肌瘤患者，随机分为两组，GnRH-a组40例，每隔4周皮下注射长效GnRH-a3.75mg，共3次；米非司酮组41例，每天口服米非司酮12．5mg，共3个月，观察治疗效果和副反应。结果：两组患者临床症状明显改善，治疗期间所有病人均闭经。肌瘤明显缩小，GnRH-a组肌瘤平均体积缩小43．5％，米非司酮组肌瘤平均体积缩小40．10％。两组治疗效果相比，差别无显著性（P＞0．05）。停药后多数病人月经逐渐恢复，恢复排卵日GnRH-a组较米非司酮组迟，肌瘤复发以米非司酮组快。结论：长效GnRH-a和米非司酮对治疗子宫肌瘤安全有效，但停药后易复发，适合于术前或围绝经期用药，无法完全代替手术治疗。     

药物治疗子宫肌瘤的疗效评价

目的评价药物治疗子宫肌瘤的疗效。方法选取2013年7月~2015年5月我院收治的子宫肌瘤患者78例为研究对象,按照使用不同药物将其分为研究组和对照组,各39例。研究组采用米非司酮进行治疗,对照组采用三烯高诺酮进行治疗。对比两组患者在用药前后子宫肌瘤的变化与相关临床指标的改变程度。结果两组患者在服药后,子宫体积与肌瘤体积明显缩小,与治疗前比较,差异有统计学意义(P0.05)。结论药物的使用对于子宫肌瘤的治疗具有较为显著的作用,可缓解或治愈患者的病情,使经期明显缩短,经量显著减少,可为手术做好提前准备。     

经导管子宫动脉栓塞术治疗子宫肌瘤的临床观察

目的 探讨经导管子宫动脉栓塞（TUAE）治疗子宫肌瘤的疗效及安全性。方法 对38例子宫肌瘤患者经导管子宫动脉注射碘油－平阳霉素乳剂行TUAE治疗,其中5例于栓塞后1－3周行全子宫切除或肌瘤剔除术,标本送病理检查;对33例随访6－12个月者,观察肌瘤与子宫体积变化及卵巢内分泌功能改变。结果 行TUAE后,患者总的症状改善率为90．6％（29／32）,其中月经完全恢复正常为90．3％（28／31）,下腹部、腰腿胀痛消失为83．3％（25／30）,尿频、尿急等压迫症状消失为45．5％（5／11）。栓塞6个月后,肌瘤与子宫体积平均缩小为59．1％和49．3％,栓塞12个月后平均缩小为61．8％和49．9％。卵巢内分泌功能栓塞前后无显著变化。手术标本病理学检查,碘油仅分布于肌瘤组织,栓塞2周后肌瘤组织出现点状坏死,3周后出现大量片状坏死,而正常子宫肌组织未见异常。结论 行TAUE治疗子宫肌瘤,近期疗效明显,对卵巢内分泌功能及正常子宫肌组织无明显影响。     

A crossover study of triptorelin and leuprorelin acetate

OBJECTIVE: To compare the potency, side effects, and duration of action of triptorelin and leuprorelin acetate after i.m. injections. DESIGN: Prospective, double-blind crossover clinical study. SETTING: A teaching hospital.Patient(s): Fifty-four patients with pelvic endometriosis. INTERVENTION(S): Twenty-seven patients had three doses of i.m. triptorelin (3.75 mg) followed by three doses of i.m. leuprorelin acetate at 4-week intervals. Twenty-one patients had three doses of i.m. leuprorelin acetate (3.75 mg) followed by three doses of i.m. triptorelin, also at 4-week intervals. MAIN OUTCOME MEASURE(S): Menopausal symptoms, time taken for menstruation to return, serum E(2), FSH, LH levels, lipid profiles, and liver function tests. RESULT(S): The potencies of triptorelin and leuprorelin acetate in lowering the serum E(2), FSH, and LH levels were comparable. The severity of menopausal symptoms, changes in the lipid profile and liver function parameters were similar after triptorelin and leuprorelin acetate. The resurgence of ovarian activities and the spontaneous return of menstruation occurred significantly earlier after leuprorelin acetate than triptorelin. CONCLUSION(S): Both drugs are equally potent in down-regulating the pituitary-ovarian function, and their side effects are similar. Triptorelin has a longer duration of drug action and can be administered over a longer interval period.     

Laparoscopic occlusion compared with embolization of uterine vessels: a randomized controlled trial

OBJECTIVE: To compare clinical outcome 6 months after treatment with bilateral laparoscopic occlusion of the uterine artery versus uterine leiomyoma embolization. METHODS: Sixty-six premenopausal women with symptomatic uterine leiomyomata were randomized to treatment with either laparoscopic occlusion of uterine arteries or uterine leiomyoma embolization. The primary outcome was reduction of blood loss from pretreatment to 6 months postoperatively, measured by a Pictorial Bleeding Assessment Chart. Secondary outcomes included patients' own assessment of symptom reduction, postoperative pain assessed using visual analog scales, ketobemidone used postoperatively, complications, secondary interventions, and failures. RESULTS: Fifty-eight women were included; 6-month follow-up data were available for 28 participants in each group. The percentage reduction in Pictorial Bleeding Assessment Chart scores did not differ between the treatment groups (52% after uterine leiomyoma embolization and 53% after laparoscopy, P=.96). The study had 52% power to detect a 20% difference on the Pictorial Bleeding Assessment Chart. Fewer participants in the group treated with uterine leiomyoma embolization complained of heavy bleeding after 6 months (4% compared with 21%, P=.044). The postoperative use of ketobemidone was higher after uterine leiomyoma embolization (46 mg compared with 12 mg, P<.001). CONCLUSION: Both laparoscopic occlusion of uterine vessels and embolizaton of uterine leiomyoma improved clinical symptoms in the majority of patients. Participants with the laparoscopic procedure had less postoperative pain but heavier menstrual bleeding 6 months after treatment. A larger study and longer follow-up is necessary before a definite conclusion can be made regarding the most effective treatment. CLINICAL TRIAL REGISTRATION: (www.ClinicalTrials.gov), NCT00277680 LEVEL OF EVIDENCE: I.     

米非司酮对子宫肌瘤及子宫肌层组织雌、孕激素受体的影响

目的 了解米非司酮对子宫肌瘤及子宫肌层组织中雌激素受体（ＥＲ）,孕激素受体（ＰＲ）的影响。方法 对２０例临床诊断为子宫肌瘤并有手术指征。无内科合并症患者（服药组）,从月经第１天起予米非司酮每日２５ｍｇ口服,连续９０ｄ,应用彩色超声检查服药前,后子宫肌瘤的变化,以及血清激素水平,血脂,肝肾功能,电解质,血常规的变化,停药后立即手术,并配对选２０例临床情况相似的子宫肌瘤患者作为对照组,用ＥＲ,ＰＲ单克     

保守性手术联合长效醋酸甲羟孕酮治疗中重度子宫内膜异位症的临床观察

目的　探讨长效醋酸甲羟孕酮 (DMPA)用于中重度子宫内膜异位症患者保守性手术后巩固治疗的临床效果及副反应。方法　将资料完整的中重度子宫内膜异位症行保守性手术治疗的患者 94例 ,分为DMPA组、促性腺激素释放激素激动剂 (GnRH a)组及对照组。DMPA组 34例 ,术后月经来潮 5d内 ,深部肌内注射DMPA 15 0mg ,2 8～ 30d注射 1次 ,共 6次 ;GnRH a组 30例 ,术后月经来潮 5d内 ,皮下注射亮丙瑞林 3 75mg ,2 8～ 30d注射 1次 ,共 6次 ;对照组 30例 ,术后未用药物治疗。观察治疗前后患者疼痛症状和体征的临床缓解情况、月经变化、体重改变、肝肾功能及性激素水平变化。结果　DMPA组及GnRH a组患者疼痛症状和体征完全缓解率分别为 88%及 93% ,显著高于对照组的 5 3% ,差异有统计学意义 (χ2 =12 2 73,P <0 0 1;χ2 =9 6 0 4 ,P <0 0 1) ,DMPA组及GnRH a组患者累积复发率分别为 6 %及 7% ,显著低于对照组的 2 7% (χ2 =5 2 2 2 ,P <0 0 5 ;χ2 =4 32 0 ,P <0 0 5 ) ,而DMPA组与GnRH a组比较 ,差异无统计学意义 (χ2 =0 4 88,P >0 0 5 ;χ2 =0 0 17,P >0 0 5 )。DMPA组用药前雌二醇水平为 (2 0 0± 15 ) pmol/L ,用药后雌二醇水平显著下降至(12 0± 9) pmol/L ,但仍维持在卵泡早期水平。GnRH a组用药前     

Pituitary desensitization for eight weeks after the administration of two distinct gonadotrophin-releasing hormone agonists

OBJECTIVE(S): The objective was to evaluate the duration of pituitary desensitization after the administration of 3.5 mg of triptorelin (T) and leuprolin (L) depot preparations in patients with endometriosis. STUDY DESIGN: Two groups of 30 patients received, on 21st day of the cycle, 3.75 mg i.m. of triptorelin (T group), and of leuprolin acetate (L group). From the first to the eighth week following gonadotrophin-releasing hormone agonists (GnRH-a) administration both groups underwent pelvic ultrasound and serum follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) evaluation. Statistical analysis was performed using the ANOVA test and the median test. A p-value < 0.05 was considered significant. RESULTS: Pituitary suppression was achieved from two to six and from two to seven weeks after the administration of 3.75 mg of leuprolin and triptorelin, respectively. FSH and LH serum levels were significantly higher in the L group than in the T group after the fourth week. CONCLUSIONS: Leuprolin and triptorelin depots (3.75 mg) promote satisfactory ovarian suppression lasting for six and seven weeks, respectively, after administration, with significantly different ambient levels of endogenous LH.     

A randomised controlled trial comparing GnRH antagonist cetrorelix with GnRH agonist leuprorelin for endometrial thinning prior to transcervical resection of endometrium

Objectives  To compare the effectiveness of leuprorelin and cetrorelix, when used as preoperative endometrial thinning agents prior to transcervical resection of endometrium (TCRE).
Design  A prospective, double-blind randomised controlled trial.
Setting  Gynaecological department of a UK district general hospital.
Participants  A total of 106 premenopausal women with dysfunctional uterine bleeding, undergoing TCRE.
Interventions  Women were equally randomised to 3.75 mg of leuprorelin acetate (3–4 weeks) or 3 mg cetrorelix (4–7 days) prior to TCRE. About 1 ml saline was given as placebo in both arms.
Main outcome measures  Amenorrhoea rate at 6 months, endometrial thickness using transvaginal ultrasound on the day of operation.
Results  A total of 100 women completed the trial with no loss to follow up. Amenorrhoea rate at 6 months after surgery was high in both groups (80% cetrorelix and 84% leuprorelin) with no statistical significance. All endometrial outcome measures including endometrial thickness on ultrasound, histology and operative appearance were more favourable in leuprorelin group as compared with cetrorelix ( P values 0.013, <0.001 and 0.003 respectively). More women in leuprorelin group had hot flushes as compared with cetrorelix (15/50 versus 6/50; P  = 0.047). No significant differences were seen in other outcome measures.
Conclusions  In dosages used, leuprorelin produced more consistent thinning of the endometrium as compared with cetrorelix, although this did not make any significant difference to operative or menstrual outcomes. The endometrial thinning effect with cetrorelix does appear to be more favourable than that seen at postmenstrual phase in other studies. The optimum (possibly higher) dosage of cetrorelix for this purpose has not yet been established.     

Comparison of triptorelin acetate vs triptorelin pamoate in the treatment of Central precocious puberty (CPP): a retrospective study

Abstract

The aim of this study is to compare the clinical and biochemical outcomes of triptorelin acetate (TPA) versus triptorelin pamoate (TPP) treatment in girls with central precocious puberty. A total of 60 patients with idiopathic CPP were retrospectively recruited. Thirty girls were treated with triptorelin acetate 3.75?mg/month (TPA group) and thirty girls in a second group received triptorelin pamoate 3.75?mg/4?weeks (TPP group). Patient follow-up at 12 and 24?months included GnRH Test at 12?months and baseline LH at 24?months. Patients were monitored with pelvic ultrasound, X-Ray of the hand and wrist and anthropometric evaluations. A total of 60/60 girls showed a good response to both formulations. Significant reductions in basal and LH peaks, estradiol values, breast pubertal stage, progression of bone age and growth velocity rate after 12?months treatment were obtained in both groups, demonstrating the equivalence of the two formulations in regulating the hypothalamic–pituitary-gonadal (HPG) axis. Triptorelin pamoate provided a more effective and significant reduction in LH peak after 12?months in comparison with triptorelin acetate more effective in reducing ovarian volume and endometrial thickness. Both formulations were equivalent, even though the LH peak was significantly lower in girls treated with triptorelin pamoate     

Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis

PURPOSE OF INVESTIGATION: Endometriosis is a common finding in women with infertility, but the mechanism by which it renders a woman infertile remains unclear. The medical treatment of pelvic endometriosis includes hormonal therapy that directly attacks endometriosis lesions or indirectly by inhibiting endometrial proliferation through estrogenic deprivation. The aim of this study was to compare the efficacy and safety of leuprorelin acetate depot and danazol for endometriosis in infertile women. METHODS: This randomized trial involved 81 women 19-41 years old with regular menses and known pelvic endometriosis who were recruited from the Fertility Center of the Second University of Naples between 1992 and 1999. Fifty-four women were given 3.75 mg of leuprolide acetate depot every 28 days for 24 weeks and the remaining 27 took 200 mg of danazol three times daily for 24 weeks. Efficacy assessments were based on pre-admission and end-of-treatment laparoscopic scores and subjective symptoms scores at 4-week intervals during and after treatment. Safety was evaluated by adverse events and clinical laboratory tests. RESULTS: In each group, endometriosis growth and symptoms significantly improved during treatment (p < 0.001). Significantly fewer patients randomized to leuprorelin acetate (5.5%) withdrew during treatment compared with 18.5% randomized to danazol (p < 0.05). After treatment symptoms returned in each group, but severity was less than at admission at all time points (p < 0.02). Hypoestrogenic side-effects were more common in those receiving leuprorelin, particularly hot flushes, but anabolic/androgenic side-effects of weight gain and acne were more common in those receiving danazol. CONCLUSION: Both leuprorelin acetate depot and danazol are effective in the treatment of endometriosis in infertile patients. The hypoestrogenic side-effects of leuprorelin may be better tolerated than the androgenic, anabolic effects of danazol.     

Symptom-Free Interval After Triptorelin Treatment of Uterine Fibroids: Long-Term Results

An increasing number of publications document regression of fibroids under treatment with gonadotropin releasing hormone (GnRH) agonists. However, recurrence after stopping treatment regularly counterbalances its benefit.

We now report on 28 patients with intramural myomas, treated with triptorelin for 4-6 months and followed for 42-56 months. During or shortly after treatment, six patients entered menopause. In this group, a volume reduction of 71% was achieved and no surgery was needed thereafter.

In 22 premenopausal women, a 64% decrease of uterine volumes was obtained at the end of treatment; the long-term reductive effect was 31%. When compared with initial values, a significant decrease was observed at the end of treatment (p=0.0001) and of follow-up (p < 0.0005).

In 13 (of 22) premenopausal patients, surgery was needed after triptorelin treatment for permanent control of fibroids. The remaining nine patients were free of symptoms after 42-56 months, having uteri in situ. These two groups differ significantly in pretreatment uterine volume (p < 0.001) and in reduction rate after therapy (p < 0.01), both parameters beinghigherin patients who finally needed surgery.

In conclusion, triptorelin treatment is definitely beneficial in perimenopausal women and in nearly half of premenopausal women, in whom hysterectomy can be prevented. In the other half, surgery is necessary, despite significant volume reduction. These results need to be corroborated on larger groups of patients. More research is needed to explain different responses to treatment in premenopausal patients.